5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 4.04▲ | 4.00▲ | 3.92▲ | 3.72▲ | 2.47▲ |
MA10 | 4.11▼ | 3.91▲ | 3.81▲ | 3.43▲ | 1.87▲ |
MA20 | 4.04▲ | 3.78▲ | 3.62▲ | 2.30▲ | 1.55▲ |
MA50 | 3.80▲ | 3.67▲ | 3.60▲ | 1.68▲ | 1.79▲ |
MA100 | 3.69▲ | 3.26▲ | 2.64▲ | 1.46▲ | 2.13▲ |
MA200 | 3.48▲ | 2.27▲ | 1.92▲ | 1.73▲ | 1.77▲ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.026▼ | 0.039▲ | 0.036▲ | 0.181▲ | 0.336▲ |
RSI | 57.210▲ | 59.457▲ | 61.737▲ | 71.067▲ | 76.161▲ |
STOCH | 13.581▼ | 74.370 | 67.861 | 76.041 | 47.426 |
WILL %R | -75.000 | -28.235 | -28.235 | -10.072▲ | -9.974▲ |
CCI | -54.523 | 90.489 | 136.565▲ | 87.239 | 198.770▲ |
Wednesday, July 16, 2025 05:49 AM
LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it ...
|
Wednesday, July 16, 2025 05:14 AM
LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it has received a letter from the Nasdaq Hearings Panel ...
|
Wednesday, July 16, 2025 05:05 AM
LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it has received a letter from the Nasdaq Hearings Panel ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
18/07/25 | 3.76 | 4.31 | 3.76 | 4.07 | 254,371 |
17/07/25 | 3.85 | 3.99 | 3.45 | 3.78 | 242,951 |
16/07/25 | 3.10 | 3.74 | 2.75 | 3.72 | 1,031,455 |
15/07/25 | 3.30 | 4.20 | 3.30 | 3.71 | 569,703 |
14/07/25 | 4.15 | 4.15 | 3.13 | 3.30 | 573,836 |
11/07/25 | 3.86 | 4.45 | 3.62 | 3.97 | 831,683 |
10/07/25 | 2.75 | 4.33 | 2.71 | 4.22 | 1,982,846 |
09/07/25 | 2.54 | 2.99 | 2.5201 | 2.75 | 1,259,037 |
08/07/25 | 2.36 | 2.73 | 2.30 | 2.53 | 1,482,503 |
07/07/25 | 2.50 | 2.65 | 2.02 | 2.24 | 2,259,898 |
|
|
||||
|
|
||||
|
|